Accession Therapeutics Limited
Rahul Khanolkar has extensive work experience in the field of research and development. Rahul is currently serving as the Pre-clinical program lead (principal scientist) at Accession Therapeutics Limited since December 2022. Prior to this role, they held the position of Pre-clinical program lead (senior scientist) at the same company from November 2021 to December 2022.
Before joining Accession Therapeutics Limited, Rahul worked at Immunocore as a Senior Scientist (Discovery Research) from January 2019 to October 2021. Rahul also worked as a Scientist (unconventional T cells) at Immunocore from November 2017 to December 2018.
Prior to their tenure at Immunocore, Rahul worked at Tusk Therapeutics as a Senior Scientist from May 2016 to October 2017.
Earlier in their career, Rahul served as a Postdoctoral Research Fellow at the University of Aberdeen from February 2014 to May 2016. Rahul also worked as a PhD student at the University of Aberdeen from September 2010 to October 2013.
Rahul Khanolkar completed their education from 1992 to 2004 at Frank Anthony Public School F.A.P.S. However, the specific degree and field of study during this period is not provided. From 2004 to 2006, they pursued a Pre-University Course in Science at Sri Bhagawan Mahaveer Jain College. Subsequently, from 2006 to 2009, they earned a Bachelor of Science (BSc) in Biotechnology from Dhempe College of Arts and Science. Finally, from 2009 to 2010, they pursued a Master's degree in Cellular and Molecular Immunology from the University of Aberdeen.
Accession Therapeutics Limited
Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells.As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour.Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.